Oramed Pharmaceuticals Inc.

NASDAQ:ORMP

Biotechnology

Healthcare
$3.89 +0.79%

+$0.03 today

Market cap
$169.16M
Beta
1.24
P/E (TTM)
1.4
EPS (TTM)
$2.70
Dividend yield
6.54%
52W Low $1.98High $5.01

Volume 0.16M

Average 0.16M

ORMP Other Non-Cash Items

Other non-cash adjustments that reconcile net income to operating cash flow.

Oramed Pharmaceuticals Inc.NASDAQ: ORMP

Other Non-Cash Items · Q1 FY2026 · quarter ended Mar 2026

Other non-cash items turns negative

Q1 FY2026 other non-cash items was -$49.08M, compared with $3.48M a year earlier. Trailing-twelve-month other non-cash items was -$136.99M.

Context

  • Other non-cash items amounted to 4263.9% of revenue in FY2025.
  • Other non-cash items increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly other non-cash items holds near -$49.08M or moves back toward the trailing-twelve-month quarterly average of -$34.25M.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$49.08M+265.5% QoQ
Last fiscal yearDec 2025
-$85.28M-1275.4% YoY
LTMMar 2026
-$136.99M-1139.7% YoY
Other Non-Cash Items past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-1511.1%——
1 year-1275.4%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Other Non-Cash Items history

USD · from the cash flow

Latest · FY2025
(85.28M) USD
Year-over-year change
-1275.4%

Other Non-Cash Items vs competitors

How ORMP compares with its peers on the latest reported figures

  • Peers report in different currencies, so other non-cash items is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -1139.7% is the lowest of 9, against a peer median of -19.6%.
ORMP Competitors
Other Non-Cash Items for ORMP and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ORMPOramed Pharmaceuticals Inc.LTM Mar 2026$136.99M USD-1139.7%——
OVIDOvid Therapeutics Inc.LTM Mar 2026$19.9M USD-29.1%+205.9%279.4%
CLNNClene Inc.LTM Mar 2026$12.53M USD+5079.4%—9353.8%
IMAImageneBio IncLTM Mar 2026$12.13M USD+1297.6%+74.2%—
IFRXInflaRx N.V.LTM Mar 2026€6.04M EUR+205.4%—20599.5%
KLRSKalaris Therapeutics IncLTM Mar 2026$5.39M USD———
COYACoya Therapeutics, Inc.LTM Mar 2026$2.3M USD—-17.1%29.0%
CNTXContext Therapeutics Inc.LTM Mar 2026$2.11M USD-85.7%+53.9%—
MGNXMacroGenics, Inc.LTM Mar 2026$1.21M USD-96.9%-31.8%0.8%
STTKShattuck Labs, Inc.LTM Mar 2026$1M USD-10.0%—100.3%
CNTBConnect Biopharma Holdings LimitedFY2025$736K USD-723.7%-18.3%1150.0%
Peer median (excluding ORMP) —-19.6%+18.4%279.4%

Competitors are the stored peer set for ORMP. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Aug 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(22.24M)(36.56M)5.53M(19.06M)64.02M
Depreciation & Amortization77K58K196K193K121K
Deferred Income Tax00007.91M
Stock-Based Compensation00005.99M
Change in Working Capital(1.32M)(943K)(2.7M)3.2M(1.91M)
Accounts Receivables00000
Inventory00000
Accounts Payables2.06M(376K)(2.23M)3.53M1.13M
Other Working Capital(3.38M)(567K)(471K)(325K)(3.04M)
Other Non-Cash Items2.3M8.75M(13.32M)7.26M(85.28M)
Operating Cash Flow(21.18M)(28.7M)(10.3M)(8.41M)(9.15M)
Capital Expenditures(375K)(496K)(254K)(18K)(1.93M)
Acquisitions (Net)1.5M24K00(7.25M)
Purchases of Investments(53.82M)(154.41M)(190.92M)(55.76M)(88.51M)
Sales of Investments30.43M185.09M118.14M161.65M96.88M
Other Investing Activities(1K)2K0(60K)6.25M
Investing Cash Flow(22.26M)30.21M(73.04M)105.82M5.44M
Debt Repayment——49.55M(49.55M)0
Common Stock Issued101.39M11.56M2.43M00
Common Stock Repurchased000(2.48M)(4.74M)
Dividends Paid00000
Other Financing Activities000(2K)0
Financing Cash Flow101.39M11.56M51.98M(52.04M)(4.74M)
Effect of Forex Changes2K(49.85M)(54K)(4K)(30K)
Net Change in Cash57.95M(36.78M)(31.41M)45.37M(8.47M)
Free Cash Flow(21.56M)(29.2M)(10.55M)(8.43M)(11.08M)

Oramed Pharmaceuticals Inc.

NASDAQ:ORMP

Intrinsic Alpha fair value

Locked

Current Price

$3.89

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.